Table 1.
Baseline demographic and characteristics of the study patients.
| Evolocumab (n = 60) | SOC (n = 60) | p | |
|---|---|---|---|
| Age, years | 60.97 ± 7.17 | 62.88 ± 9.13 | 0.203a |
| Male gender, n (%) | 46 (76.67) | 38 (63.33) | 0.111b |
| Body mass index, kg/m2 | 25.04 ± 2.99 | 24.03 ± 4.06 | 0.125a |
| Active smoking, n (%) | 25 (41.67) | 13 (21.67) | 0.019b |
| Diabetes mellitus, n (%) | 21 (35.0) | 22 (36.67) | 0.849b |
| Hypertension, n (%) | 47 (78.33) | 40 (66.67) | 0.152b |
| History of CHD, n (%) | 4 (6.67) | 6 (10.0) | 0.053c |
| First onset, n (%) | 39 (65.0) | 41 (68.33) | 0.698b |
| Prior statin treatment, n (%) | 6 (10.0) | 3 (5.0) | 0.268c |
| NIHSS score | 3.28 ± 3.07 | 2.25 ± 1.51 | 0.022a |
| LDL-C, mmol/L | 3.15 ± 0.96 | 3.17 ± 0.83 | 0.915a |
| TC, mmol/L | 4.12 ± 1.30 | 4.22 ± 1.18 | 0.676a |
| TG, mmol/L | 1.68 ± 1.07 | 1.61 ± 0.74 | 0.674a |
| HDL-C, mmol/L | 1.04 ± 0.26 | 1.05 ± 0.30 | 0.895a |
| ApoA1, mmol/L | 1.25 ± 0.25 | 1.25 ± 0.27 | 0.913a |
| ApoB, mmol/L | 0.92 ± 0.35 | 0.98 ± 0.30 | 0.305a |
| Lp(a), mmol/L | 88.40 ± 117.30 | 72.93 ± 96.86 | 0.432a |
| hs-CRP, mg/L | 7.42 ± 12.07 | 15.06 ± 26.63 | 0.046a |
| ESR, mm/h | 24.05 ± 16.79 | 24.33 ± 22.71 | 0.938a |
| ALT, U/L | 19.77 ± 13.09 | 22.55 ± 16.40 | 0.306a |
| AST, U/L | 19.17 ± 6.26 | 21.77 ± 9.19 | 0.073a |
SOC, standard of care; CHD, coronary heart disease; NIHSS, National Institutes of Health Stroke Scale; LDL-C, low-density lipoprotein cholesterol; TC, total cholesterol; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; Apo, apolipoprotein; Lp(a), lipoprotein(a); hs-CRP, high-sensitivity C-reactive protein; ESR, erythrocyte sedimentation rate; ALT, alanine aminotransferase; AST, aspartate aminotransferase.
a
t-test.
b
Chi-square.
c
Fisher exact test.